Molecular imaging of neuroendocrine tumors

References

• Blasberg RG. Imaging update: new windows, new views. Clin. Cancer Res.13, 3444–3448 (2007).
   PubMedGoogle Scholar
• Kelloff GJ, Krohn KA, Larson SM et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin. Cancer. Res.11, 7967–7985 (2005).
   PubMed Web of Science ®Google Scholar
• Mankoff DA, Krohn KA. PET imaging of response and resistance to cancer therapay. In: Drug Resistance In Cancer. Teicher B (Ed.). Humana Press, Edition Totowa, NJ, USA 105–122 (2006).
   Google Scholar
• Janson ET, Oberg K. Malignant neuroendocrine tumors. Cancer Chemother. Biol. Response Modif.20, 463–470 (2002).
   PubMedGoogle Scholar
• Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro–enteropancreatic endocrine tumors. J. Mol. Med.76, 413–420 (1998).
   PubMedGoogle Scholar
• Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med.28, 836–846 (2001).
   PubMedGoogle Scholar
• Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging30, 781–793 (2003).
   PubMed Web of Science ®Google Scholar
• Krenning EP, Bakker WH, Kooij PP et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J. Nucl. Med.33, 652–658 (1992).
   PubMed Web of Science ®Google Scholar
• Krenning EP, Kwekkeboom DJ, Bakker WH et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med.20, 716–731 (1993).
   PubMedGoogle Scholar
• Gibril F, Reynolds JC, Doppman JL et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann. Intern. Med.125, 26–34 (1996).
   PubMed Web of Science ®Google Scholar
• Lebtahi R, Cadiot G, Sarda L et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J. Nucl. Med.38, 853–858 (1997).
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Kooij PP, Bakker WH et al. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med.40, 762–767 (1999).
   PubMedGoogle Scholar
• Wild D, Macke HR, Waser B et al.68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur. J. Nucl. Med. Mol. Imaging32, 724 (2005).
   PubMedGoogle Scholar
• Ginj M, Chen J, Walter MA et al. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin. Cancer Res.11, 1136–1145 (2005).
   PubMed Web of Science ®Google Scholar
• Hubalewska-Dydejczyk A, Fross-Baron K, Mikolajczak R et al.99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years’ experience. Eur. J. Nucl. Med. Mol. Imaging33, 1123–1133 (2006).
   PubMed Web of Science ®Google Scholar
• Storch D, Behe M, Walter MA et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In–DOTA0,Tyr3, Thr8]octreotide and [111In–DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J. Nucl. Med.46, 1561–1569 (2005).
   PubMed Web of Science ®Google Scholar
• Gabriel M, Decristoforo C, Donnemiller E et al. An intrapatient comparison of 99mTc–EDDA/HYNIC-TOC with 111In–DTPA–octreotide for diagnosis of somatostatin receptor-expressing tumors. J. Nucl. Med.44, 708–716 (2003).
   PubMedGoogle Scholar
• Gabriel M, Decristoforo C, Maina T et al.99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an intrapatient comparison of two novel Technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother. Radiopharm.19, 73–79 (2004).
   PubMedGoogle Scholar
• Decristoforo C, Maina T, Nock B et al.99mTc-demotate 1: first data in tumour patients-results of a pilot/Phase I study. Eur. J. Nucl. Med. Mol. Imaging30, 1211–1219 (2003).
   PubMedGoogle Scholar
• Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. Radiolabeled somatostatin analog [177Lu–DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol.23, 2754–2762 (2005).
   PubMed Web of Science ®Google Scholar
• Esser JP, Krenning EP, Teunissen JJ et al. Comparison of [177Lu-DOTA(0),Tyr(3)]octreotate and [177Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur. J. Nucl. Med. Mol. Imaging33, 1346–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Bombardieri E, Aktolun C, Baum RP et al.111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur. J. Nucl. Med. Mol. Imaging30, BP140–147 (2003).
   PubMedGoogle Scholar
• Schillaci O, Scopinaro F, Angeletti S et al. SPECT improves accuracy of somatostatin receptor scintigraphy in abdominal carcinoid tumors. J. Nucl. Med.37, 1452–1456 (1996).
   PubMedGoogle Scholar
• Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol.15, 966–973 (2004).
   PubMed Web of Science ®Google Scholar
• Granberg D, Sundin A, Janson ET et al. Octreoscan in patients with bronchial carcinoid tumours. Clin. Endocrinol. (Oxf.)59, 793–799 (2003).
   PubMed Web of Science ®Google Scholar
• de Herder WW, Kwekkeboom DJ, Valkema R et al. Neuroendocrine tumors and somatostatin: imaging techniques. J. Endocrinol. Invest.28, 132–136 (2005).
   PubMedGoogle Scholar
• Dromain C, de Baere T, Lumbroso J et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol.23, 70–78 (2005).
   PubMed Web of Science ®Google Scholar
• Termanini B, Gibril F, Reynolds JC et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology112, 335–347 (1997).
   PubMed Web of Science ®Google Scholar
• Lebtahi R, Le Cloirec J, Houzard C et al. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J. Nucl. Med.43, 889–895 (2002).
   PubMed Web of Science ®Google Scholar
• Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J. Nucl. Med.41, 1704–1713 (2000).
   PubMed Web of Science ®Google Scholar
• Janson ET, Westlin JE, Eriksson B et al. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur. J. Endocrinol.131, 577–581 (1994).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J. Nucl. Med.46(Suppl. 1), 67S–75S (2005).
   PubMed Web of Science ®Google Scholar
• Hattner RS, Huberty JP, Engelstad BL et al. Localization of m-iodo(131I)benzylguanidine in neuroblastoma. AJR Am. J. Roentgenol.143, 373–374 (1984).
   PubMedGoogle Scholar
• Nakajo M, Shapiro B, Copp J et al. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. J. Nucl. Med.24, 672–682 (1983).
   PubMed Web of Science ®Google Scholar
• Shapiro B, Copp JE, Sisson JC et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J. Nucl. Med.26, 576–585 (1985).
   PubMed Web of Science ®Google Scholar
• Kaltsas G, Korbonits M, Heintz E et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J. Clin. Endocrinol. Metab.86, 895–902 (2001).
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Logvinski T, Yong-Hing C et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med.47, 223–233 (2006).
   PubMed Web of Science ®Google Scholar
• Mukherjee JJ, Kaltsas GA, Islam N et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine [131I-mIBG]. Clin. Endocrinol. (Oxf.)55, 47–60 (2001).
   PubMed Web of Science ®Google Scholar
• Buscombe JR, Cwikla JB, Caplin ME, Hilson AJ. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response. Nucl. Med. Commun.26, 969–976 (2005).
   PubMed Web of Science ®Google Scholar
• Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin. Nucl. Med.36, 228–247 (2006).
   PubMed Web of Science ®Google Scholar
• Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med.16, 210–224 (1975).
   PubMed Web of Science ®Google Scholar
• Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology189, 847–850 (1993).
   PubMed Web of Science ®Google Scholar
• von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology238, 405–422 (2006).
   PubMed Web of Science ®Google Scholar
• Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J. Nucl. Med.42, 1S–93S (2001).
   PubMedGoogle Scholar
• Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J. Nucl. Med.47, 451–469 (2006).
   PubMedGoogle Scholar
• Chin BB, Wahl RL. 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut52(Suppl. 4), iv23–iv29 (2003).
   PubMedGoogle Scholar
• Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin. Nucl. Med.36, 169–181 (2006).
   PubMed Web of Science ®Google Scholar
• Juweid ME, Cheson BD. Role of positron emission tomography in lymphoma. J. Clin. Oncol.23, 4577–4580 (2005).
   PubMed Web of Science ®Google Scholar
• Kapoor V, Fukui MB, McCook BM. Role of 18FFDG PET/CT in the treatment of head and neck cancers: principles, technique, normal distribution, and initial staging. AJR Am. J. Roentgenol.184, 579–587 (2005).
   PubMedGoogle Scholar
• Adams S, Baum R, Rink T et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur. J. Nucl. Med.25, 79–83 (1998).
   PubMedGoogle Scholar
• Pasquali C, Rubello D, Sperti C et al. Neuroendocrine tumor imaging: can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior? World J. Surg.22, 588–592 (1998).
   PubMed Web of Science ®Google Scholar
• Foidart-Willems J, Depas G, Vivegnis D. Positron emission tomography and radio labeled octreotide scintigraphy in carcinoid tumors. Eur. J. Nucl. Med.22, 635–638 (1995).
   Google Scholar
• Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J. Nucl. Med.38, 1382–1383 (1997).
   PubMedGoogle Scholar
• Pearse AG. The APUD concept and hormone production. Clin. Endocrinol. Metab.9, 211–222 (1980)
   PubMedGoogle Scholar
• Ahlstrom H, Eriksson B, Bergstrom M et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology195, 333–337 (1995).
   PubMed Web of Science ®Google Scholar
• Hoegerle S, Altehoefer C, Ghanem N et al. Whole-body 18F DOPA PET for detection of gastrointestinal carcinoid tumors. Radiology220, 373–380 (2001).
   PubMed Web of Science ®Google Scholar
• Becherer A, Szabo M, Karanikas G et al. Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET. J. Nucl. Med.45, 1161–1167 (2004).
   PubMedGoogle Scholar
• Koopmans KP, de Vries EG, Kema IP et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol.7, 728–734 (2006).
   PubMedGoogle Scholar
• Montravers F, Grahek D, Kerrou K et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med.47, 1455–1462 (2006).
   PubMed Web of Science ®Google Scholar
• Hoegerle S, Altehoefer C, Ghanem N et al.18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med.28, 64–71 (2001).
   PubMedGoogle Scholar
• Nanni C, Rubello D, Fanti S. 18F-DOPA PET/CT and neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging33, 509–513 (2006).
   PubMedGoogle Scholar
• Orlefors H, Sundin A, Ahlstrom H et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J. Clin. Oncol.16, 2534–2541 (1998).
   PubMed Web of Science ®Google Scholar
• Orlefors H, Sundin A, Lu L et al. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging33, 60–65 (2006).
   PubMed Web of Science ®Google Scholar
• Brown WD, Oakes TR, DeJesus OT et al. Fluorine-18-fluoro-L-DOPA dosimetry with carbidopa pretreatment. J. Nucl. Med.39, 1884–1891 (1998).
   PubMedGoogle Scholar
• Orlefors H, Sundin A, Garske U et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J. Clin. Endocrinol. Metab.90, 3392–3400 (2005).
   PubMed Web of Science ®Google Scholar
• Hofmann M, Maecke H, Borner R et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med.28, 1751–1757 (2001).
   PubMedGoogle Scholar
• Kowalski J, Henze M, Schuhmacher J et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol.5, 42–48 (2003).
   PubMedGoogle Scholar
• Koukouraki S, Strauss LG, Georgoulias V et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol Imaging33, 460–466 (2006).
   PubMed Web of Science ®Google Scholar
• Win Z, Rahman L, Murrell J et al. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur. J. Nucl. Med. Mol Imaging33, 506 (2006).
   PubMed Web of Science ®Google Scholar
• Gabriel M, Decristoforo C, Kendler D et al.68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med.48, 508–518 (2007).
   PubMed Web of Science ®Google Scholar
• Kayani I, Bomanji JB, Groves A et al. Functional imaging of neuroendocrine tumors with combined PET/CT using (68)Ga-DOTATATE (DOTA-DPhe(1),Tyr(3)-octreotate) and (18)F-FDG. Cancer112, 2447–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. North Am.43, 169–187 (2005).
   PubMed Web of Science ®Google Scholar
• Haubner R, Wester HJ, Burkhart F et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med.42, 326–336 (2001).
   PubMed Web of Science ®Google Scholar
• Dehdashti F, Grigsby PW, Mintun MA et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response – a preliminary report. Int. J. Radiat. Oncol. Biol. Phys.55, 1233–1238 (2003).
   PubMed Web of Science ®Google Scholar
• Rajendran JG, Schwartz DL, O’Sullivan J et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin. Cancer Res.12, 5435–5441 (2006).
   PubMed Web of Science ®Google Scholar
• Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J. Nucl. Med.49(Suppl. 2), 129S–148S (2008).
   Web of Science ®Google Scholar
• Hendrikse NH, de Vries EG, Eriks-Fluks L et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood–brain barrier. Cancer Res.59, 2411–2416 (1999).
   PubMed Web of Science ®Google Scholar
• Sasongko L, Link JM, Muzi M et al. Imaging P-glycoprotein transport activity at the human blood–brain barrier with positron emission tomography. Clin. Pharmacol. Ther.77, 503–514 (2005).
   PubMed Web of Science ®Google Scholar
• Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol. Clin. North Am.43, 153–167 (2005).
   PubMedGoogle Scholar
• Grierson JR, Shields AF. Radiosynthesis of 3´-deoxy-3´-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl. Med. Biol.27, 143–156 (2000).
   PubMedGoogle Scholar
• Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J. Nucl. Med.49(Suppl. 2), 64S–80S (2008).
   PubMed Web of Science ®Google Scholar
• Blankenberg FG, Katsikis PD, Tait JF et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J. Nucl. Med.40, 184–191 (1999).
   PubMed Web of Science ®Google Scholar
• Wicki A, Wild D, Storch D et al. [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin. Cancer Res.13, 3696–3705 (2007).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Latich I, Zikusoka M et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J. Clin. Gastroenterol.40, 572–582 (2006).
   PubMedGoogle Scholar